Myeloid-derived suppressor cells in B cell malignancies.

Abstract

Tumor cells use several mechanisms such as soluble immune modulators or suppressive immune cells to evade from anti-tumor responses. Immunomodulatory cytokines, such as transforming growth factor-β, interleukin (IL)-10, and IL-35, soluble factors, such as adenosine, immunosuppressive cells, such as regulatory T cells, NKT cells and myeloid-derived suppressor cells (MDSCs), are the main orchestra leaders involved in immune suppression in cancer by which tumor cells can freely expand without immune cell-mediated interference. Among them, MDSCs have attracted much attention as they represent a heterogenous population derived from myeloid progenitors that are expanded in tumor condition and can also shift toward other myeloid cells, such as macrophages and dendritic cells, after tumor clearing. MDSCs exert their immunosuppressive effects through various immune and non-immune mechanisms which make them as potent tumor-promoting cells. Although, there are several studies regarding the immunobiology of MDSCs in different solid tumors, little is known about the precise characteristics of these cells in hematological malignancies, particularly B cell malignancies. In this review, we tried to clarify the precise role of MDSCs in B cell-derived malignancies.

• Authors: Yaghoub Yazdani, Mousa Mohammadnia-Afrouzi, Mehdi Yousefi, Enayat Anvari, Ghasem Ghalamfarsa, Hadi Hasannia, Sanam Sadreddini, Farhad Jadidi-Niaragh
• Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (Tumour Biol) Vol. 36 Issue 10 Pg. 7339-53 (Sep 2015) ISSN: 1423-0380 [Electronic] Netherlands
• PMID: 26330296 (Publication Type: Journal Article, Review)

Topics

• Animals
• B-Lymphocytes (immunology, pathology)
• Humans
• Immunity, Cellular (immunology)
• Myeloid Cells (immunology)
• Neoplasms (immunology, pathology)